No Data
Cognition Therapeutics Provided an Update on Phase 2 'SHINE' Study Analysis
Express News | Cognition Therapeutics Inc -Topline Results in Second Dementia Indication Expected to Be Reported in December 2024
Express News | Cognition Therapeutics Announces All Participants Have Completed Their Final Visits in the Phase 2 Shimmer Study of Ct1812 in Dementia With Lewy Bodies
Cognition Therapeutics Announces All Participants Have Completed Their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia With Lewy Bodies
Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.
Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients With Lower Plasma P-tau217 Correlated With Improvements in Key Indicators of Alzheimer's Disease Biology
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}